Abstract
A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.
| Original language | English |
|---|---|
| Pages (from-to) | 506-508 |
| Number of pages | 3 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 16 |
| Issue number | 6 |
| State | Published - Jan 1 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix : A Gynecologic Oncology Group study. / Feun, Lynn G; Blessing, J. A.; Barrett, R. J.; Hanjani, P.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 6, 01.01.1993, p. 506-508.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix
T2 - A Gynecologic Oncology Group study
AU - Feun, Lynn G
AU - Blessing, J. A.
AU - Barrett, R. J.
AU - Hanjani, P.
PY - 1993/1/1
Y1 - 1993/1/1
N2 - A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.
AB - A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.
UR - http://www.scopus.com/inward/record.url?scp=0027333359&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027333359&partnerID=8YFLogxK
M3 - Article
C2 - 8256767
AN - SCOPUS:0027333359
VL - 16
SP - 506
EP - 508
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 6
ER -